메뉴 건너뛰기




Volumn 157, Issue 4, 2012, Pages 413-425

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012

Author keywords

JAK inhibitors; Myelofibrosis; Splenectomy; Stem cell transplant

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL MARKER; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RAPAMYCIN; RUXOLITINIB; TACROLIMUS; THYMOCYTE ANTIBODY; TOFACITINIB;

EID: 84859986297     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09107.x     Document Type: Review
Times cited : (44)

References (75)
  • 3
    • 77956482194 scopus 로고    scopus 로고
    • Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT
    • Alchalby, H., Badbaran, A., Bock, O., Fehse, B., Bacher, U., Zander, A.R. & Kroger, N. (2010b) Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplantation, 45, 1404-1407.
    • (2010) Bone Marrow Transplantation , vol.45 , pp. 1404-1407
    • Alchalby, H.1    Badbaran, A.2    Bock, O.3    Fehse, B.4    Bacher, U.5    Zander, A.R.6    Kroger, N.7
  • 9
    • 77949399433 scopus 로고    scopus 로고
    • Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis
    • Berneman, Z.N., Anguille, S., Van Marck, V., Schroyens, W.A. & Van Tendeloo, V.F. (2010) Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. British Journal of Haematology, 149, 152-155.
    • (2010) British Journal of Haematology , vol.149 , pp. 152-155
    • Berneman, Z.N.1    Anguille, S.2    Van Marck, V.3    Schroyens, W.A.4    Van Tendeloo, V.F.5
  • 10
    • 0025282373 scopus 로고
    • A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors, acute graft-versus-host disease and splenectomy
    • Boström, L., Ringdén, O., Jacobsen, N., Zwaan, F. & Nilsson, B. (1990) A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors, acute graft-versus-host disease and splenectomy. Transplantation, 49, 1100-1105.
    • (1990) Transplantation , vol.49 , pp. 1100-1105
    • Boström, L.1    Ringdén, O.2    Jacobsen, N.3    Zwaan, F.4    Nilsson, B.5
  • 11
    • 0034057313 scopus 로고    scopus 로고
    • Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect
    • Byrne, J.L., Beshti, H., Clark, D., Ellis, I., Haynes, A.P., Das-Gupta, E. & Russell, N.H. (2000) Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. British Journal of Haematology, 108, 430-433.
    • (2000) British Journal of Haematology , vol.108 , pp. 430-433
    • Byrne, J.L.1    Beshti, H.2    Clark, D.3    Ellis, I.4    Haynes, A.P.5    Das-Gupta, E.6    Russell, N.H.7
  • 14
    • 0033794885 scopus 로고    scopus 로고
    • Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect
    • Cervantes, F., Rovira, M., Urbano-Ispizua, A., Rozman, M., Carreras, E. & Montserrat, E. (2000) Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplantation, 26, 697-699.
    • (2000) Bone Marrow Transplantation , vol.26 , pp. 697-699
    • Cervantes, F.1    Rovira, M.2    Urbano-Ispizua, A.3    Rozman, M.4    Carreras, E.5    Montserrat, E.6
  • 19
    • 79959835612 scopus 로고    scopus 로고
    • Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis
    • Deeg, H.J. & Appelbaum, F.R. (2011) Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. Blood, 117, 7185.
    • (2011) Blood , vol.117 , pp. 7185
    • Deeg, H.J.1    Appelbaum, F.R.2
  • 21
  • 24
    • 0029767865 scopus 로고    scopus 로고
    • Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system
    • Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. & Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013-1018.
    • (1996) Blood , vol.88 , pp. 1013-1018
    • Dupriez, B.1    Morel, P.2    Demory, J.L.3    Lai, J.L.4    Simon, M.5    Plantier, I.6    Bauters, F.7
  • 27
    • 0033135848 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study
    • Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., de Witte, T., Deeg, H.J. & Gluckman, E. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93, 2831-2838.
    • (1999) Blood , vol.93 , pp. 2831-2838
    • Guardiola, P.1    Anderson, J.E.2    Bandini, G.3    Cervantes, F.4    Runde, V.5    Arcese, W.6    Bacigalupo, A.7    Przepiorka, D.8    O'Donnell, M.R.9    Polchi, P.10    Buzyn, A.11    Sutton, L.12    Cazals-Hatem, D.13    Sale, G.14    de Witte, T.15    Deeg, H.J.16    Gluckman, E.17
  • 29
    • 70349160401 scopus 로고    scopus 로고
    • A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis
    • Gupta, V., Kröger, N., Aschan, J., Xu, W., Leber, B., Dalley, C., Sabloff, M., Lipton, J.H., Messner, H. & Brune, M. (2009) A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplantation, 44, 317-320.
    • (2009) Bone Marrow Transplantation , vol.44 , pp. 317-320
    • Gupta, V.1    Kröger, N.2    Aschan, J.3    Xu, W.4    Leber, B.5    Dalley, C.6    Sabloff, M.7    Lipton, J.H.8    Messner, H.9    Brune, M.10
  • 31
    • 39349106820 scopus 로고    scopus 로고
    • Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies
    • Ho, V.T., Revta, C. & Richardson, P.G. (2008) Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplantation, 41, 229-237.
    • (2008) Bone Marrow Transplantation , vol.41 , pp. 229-237
    • Ho, V.T.1    Revta, C.2    Richardson, P.G.3
  • 33
    • 77449126735 scopus 로고    scopus 로고
    • International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
    • Hussein, K., Pardanani, A.D., Van Dyke, D.L., Hanson, C.A. & Tefferi, A. (2010) International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood, 115, 496-499.
    • (2010) Blood , vol.115 , pp. 496-499
    • Hussein, K.1    Pardanani, A.D.2    Van Dyke, D.L.3    Hanson, C.A.4    Tefferi, A.5
  • 34
    • 0029154317 scopus 로고
    • A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia
    • Kalhs, P., Schwarzinger, I., Anderson, G., Mori, M., Clift, R.A., Storb, R., Buckner, C.D., Appelbaum, F.R., Hansen, J.A. & Sullivan, K.M. (1995) A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. Blood, 86, 2028-2032.
    • (1995) Blood , vol.86 , pp. 2028-2032
    • Kalhs, P.1    Schwarzinger, I.2    Anderson, G.3    Mori, M.4    Clift, R.A.5    Storb, R.6    Buckner, C.D.7    Appelbaum, F.R.8    Hansen, J.A.9    Sullivan, K.M.10
  • 36
    • 33846880278 scopus 로고    scopus 로고
    • Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
    • Kroger, N., Badbaran, A., Holler, E., Hahn, J., Kobbe, G., Bornhauser, M., Reiter, A., Zabelina, T., Zander, A.R. & Fehse, B. (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood, 109, 1316-1321.
    • (2007) Blood , vol.109 , pp. 1316-1321
    • Kroger, N.1    Badbaran, A.2    Holler, E.3    Hahn, J.4    Kobbe, G.5    Bornhauser, M.6    Reiter, A.7    Zabelina, T.8    Zander, A.R.9    Fehse, B.10
  • 37
    • 61949135475 scopus 로고    scopus 로고
    • JAK2-V617F- triggered pre-emptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation
    • Kroger, N., Alchalby, H., Klyuchnikov, E., Badbaran, A., Hildebrandt, Y., Ayuk, F., Bacher, U., Bock, O., Kvasnicka, M., Fehse, B. & Zander, A. (2009b) JAK2-V617F- triggered pre-emptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood, 113, 1866-1868.
    • (2009) Blood , vol.113 , pp. 1866-1868
    • Kroger, N.1    Alchalby, H.2    Klyuchnikov, E.3    Badbaran, A.4    Hildebrandt, Y.5    Ayuk, F.6    Bacher, U.7    Bock, O.8    Kvasnicka, M.9    Fehse, B.10    Zander, A.11
  • 41
    • 0035312989 scopus 로고    scopus 로고
    • Splenectomy and hemopoietic stem cell transplantation for myelofibrosis
    • Li, Z., Gooley, T., Applebaum, F.R. & Deeg, H.J. (2001) Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood, 97, 2180-2181.
    • (2001) Blood , vol.97 , pp. 2180-2181
    • Li, Z.1    Gooley, T.2    Applebaum, F.R.3    Deeg, H.J.4
  • 45
    • 33745811661 scopus 로고    scopus 로고
    • Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
    • Mesa, R.A., Nagorney, D.S., Schwager, S., Allred, J. & Tefferi, A. (2006) Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer, 107, 361-370.
    • (2006) Cancer , vol.107 , pp. 361-370
    • Mesa, R.A.1    Nagorney, D.S.2    Schwager, S.3    Allred, J.4    Tefferi, A.5
  • 47
    • 84855588064 scopus 로고    scopus 로고
    • Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk
    • Nivison-Smith, I., Dodds, A.J., Butler, J., Bradstock, K.F., Ma, D.D., Simpson, J.M. & Szer, J. (2012) Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk. Biology of Blood and Marrow Transplantation, 18, 302-308.
    • (2012) Biology of Blood and Marrow Transplantation , vol.18 , pp. 302-308
    • Nivison-Smith, I.1    Dodds, A.J.2    Butler, J.3    Bradstock, K.F.4    Ma, D.D.5    Simpson, J.M.6    Szer, J.7
  • 48
    • 78349287650 scopus 로고    scopus 로고
    • CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway
    • Park, H.B., Oh, K., Garmaa, N., Seo, M.W., Byoun, O.J., Lee, H.Y. & Lee, D.S. (2010) CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway. Transplantation, 90, 825-835.
    • (2010) Transplantation , vol.90 , pp. 825-835
    • Park, H.B.1    Oh, K.2    Garmaa, N.3    Seo, M.W.4    Byoun, O.J.5    Lee, H.Y.6    Lee, D.S.7
  • 49
  • 51
    • 77956439565 scopus 로고    scopus 로고
    • A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
    • Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., Pascutto, C., Lazzarino, M. & Cazzola, M. (2010b) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia, 24, 1574-1579.
    • (2010) Leukemia , vol.24 , pp. 1574-1579
    • Passamonti, F.1    Rumi, E.2    Pietra, D.3    Elena, C.4    Boveri, E.5    Arcaini, L.6    Roncoroni, E.7    Astori, C.8    Merli, M.9    Boggi, S.10    Pascutto, C.11    Lazzarino, M.12    Cazzola, M.13
  • 54
    • 20844457922 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia
    • Myeloproliferative Diseases-Research Consortium.
    • Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J.T., Popat, U., Alessandrino, E.P., Spivak, J.L., Smith, B.D., Klingemann, H.G., Fruchtman, S., Hoffman, R. & Myeloproliferative Diseases-Research Consortium (2005) Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 105, 4115-4119.
    • (2005) Blood , vol.105 , pp. 4115-4119
    • Rondelli, D.1    Barosi, G.2    Bacigalupo, A.3    Prchal, J.T.4    Popat, U.5    Alessandrino, E.P.6    Spivak, J.L.7    Smith, B.D.8    Klingemann, H.G.9    Fruchtman, S.10    Hoffman, R.11
  • 55
    • 78649673010 scopus 로고    scopus 로고
    • First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol
    • Myeloproliferative Disorders Research Consortium, (suppl; abstr 6535)
    • Rondelli, D., Boyer, M., Isola, L., Shore, T., Bacigalupo, A., Klisovic, R.B., Marchioli, R., Goldberg, J.D., Hoffman, R., Silverman, L.R. & Myeloproliferative Disorders Research Consortium (2010) First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol. Journal of Clinical Oncology, 28, 15s. (suppl; abstr 6535)
    • (2010) Journal of Clinical Oncology , vol.28
    • Rondelli, D.1    Boyer, M.2    Isola, L.3    Shore, T.4    Bacigalupo, A.5    Klisovic, R.B.6    Marchioli, R.7    Goldberg, J.D.8    Hoffman, R.9    Silverman, L.R.10
  • 60
    • 75449097356 scopus 로고    scopus 로고
    • Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis
    • Snyder, D.S., Palmer, J., Gaal, K., Stein, A.S., Pullarkat, V., Sahebi, F., Vora, N., Nakamura, R. & Forman, S.J. (2010) Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biology of Blood and Marrow Transplantation, 16, 281-286.
    • (2010) Biology of Blood and Marrow Transplantation , vol.16 , pp. 281-286
    • Snyder, D.S.1    Palmer, J.2    Gaal, K.3    Stein, A.S.4    Pullarkat, V.5    Sahebi, F.6    Vora, N.7    Nakamura, R.8    Forman, S.J.9
  • 61
    • 23944440464 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
    • Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 2912-2919.
    • (2005) Blood , vol.106 , pp. 2912-2919
    • Sorror, M.L.1    Maris, M.B.2    Storb, R.3    Baron, F.4    Sandmaier, B.M.5    Maloney, D.G.6    Storer, B.7
  • 62
    • 34250624828 scopus 로고    scopus 로고
    • Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation
    • Steckel, N.K., Koldehoff, M., Ditschkowski, M., Beelen, D.W. & Elmaagacli, A.H. (2007) Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation, 83, 1518-1520.
    • (2007) Transplantation , vol.83 , pp. 1518-1520
    • Steckel, N.K.1    Koldehoff, M.2    Ditschkowski, M.3    Beelen, D.W.4    Elmaagacli, A.H.5
  • 65
    • 77949366004 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act
    • Tefferi, A. (2010) Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplantation, 45, 419-421.
    • (2010) Bone Marrow Transplantation , vol.45 , pp. 419-421
    • Tefferi, A.1
  • 66
    • 79953711716 scopus 로고    scopus 로고
    • How I treat myelofibrosis
    • Tefferi, A. (2011) How I treat myelofibrosis. Blood, 117, 3494-3504.
    • (2011) Blood , vol.117 , pp. 3494-3504
    • Tefferi, A.1
  • 69
    • 42449124578 scopus 로고    scopus 로고
    • Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
    • Tefferi, A., Lasho, T.L., Huang, J., Finke, C., Mesa, R.A., Li, C.Y., Wu, W., Hanson, C.A. & Pardanani, A. (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia, 22, 756-761.
    • (2008) Leukemia , vol.22 , pp. 756-761
    • Tefferi, A.1    Lasho, T.L.2    Huang, J.3    Finke, C.4    Mesa, R.A.5    Li, C.Y.6    Wu, W.7    Hanson, C.A.8    Pardanani, A.9
  • 71
    • 74249123815 scopus 로고    scopus 로고
    • JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    • Tefferi, A., Lasho, T.L., Patnaik, M.M., Finke, C.M., Hussein, K., Hogan, W.J., Elliott, M.A., Litzow, M.R., Hanson, C.A. & Pardanani, A. (2010b) JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia, 24, 105-109.
    • (2010) Leukemia , vol.24 , pp. 105-109
    • Tefferi, A.1    Lasho, T.L.2    Patnaik, M.M.3    Finke, C.M.4    Hussein, K.5    Hogan, W.J.6    Elliott, M.A.7    Litzow, M.R.8    Hanson, C.A.9    Pardanani, A.10
  • 72
    • 79954433836 scopus 로고    scopus 로고
    • Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study
    • Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T. & Pardanani, A. (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Journal of Clinical Oncology, 29, 1356-1363.
    • (2011) Journal of Clinical Oncology , vol.29 , pp. 1356-1363
    • Tefferi, A.1    Vaidya, R.2    Caramazza, D.3    Finke, C.4    Lasho, T.5    Pardanani, A.6
  • 75
    • 84860002505 scopus 로고    scopus 로고
    • Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation
    • Abstract 1951.
    • Wong, K.M., Atenafu, E.G., Kim, D., Kuruvilla, J., Lipton, J.H., Messner, H.A. & Gupta, V. (2011) Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood (ASH Annual Meeting Abstracts), 118, Abstract 1951.
    • (2011) Blood (ASH Annual Meeting Abstracts) , vol.118
    • Wong, K.M.1    Atenafu, E.G.2    Kim, D.3    Kuruvilla, J.4    Lipton, J.H.5    Messner, H.A.6    Gupta, V.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.